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SEROPREVALENCE OF HEPATITIS B AND C INFECTION MARKERS AMONG CHILDREN AND 
ADOLESCENTS IN THE SOUTHERN BRAZILIAN REGION
Andréa do LIVRAMENTO(1), Caio Mauricio Mendes de CORDOVA(2), Celso SPADA(3) & Arício TREITINGER(3)
SUMMARY
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. 
The aim of this study was to determine the prevalence of HBV and HCV serological markers among children and adolescents and 
verify the epidemiology of the HBV infection over than a decade of the introduction of vaccination program. Serologic markers to 
HBsAg, total anti-HBc and anti-HCV had been tested in 393 samples. The seropositivity for HBsAg was 0.76% and for total anti-
HBc was 1.02%. Copositivity between HBsAg and total anti-HBc was verified in 0.76% of the analyzed samples. There was no 
seropositivity for anti-HCV marker. The seroprevalence of HBV infection markers among children and adolescents in the southern 
Brazilian region is high compared to that reported in other countries. Preventive measures, such as educational activities in addition 
to the universal childhood HBV vaccination, should be initiated in order to reduce the morbimortality and the economic burden 
associated with the disease.
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INTRODUCTION
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account 
for a substantial proportion of liver diseases worldwide. An estimated 
amount of two billion people have been infected with the hepatitis B virus 
and over 350 million have chronic liver infections. About 25% of adults 
who become chronically infected during childhood die from HBV-related 
liver cancer or cirrhosis45. HCV infections are also common worldwide. It 
is estimated that about 3% of the world’s population has been infected with 
HCV and that some 170 million are chronic carriers at risk of developing 
liver cirrhosis and/or liver cancer. These chronic carriers represent a 
reservoir sufficiently large for HCV to persist44. 
The hepatitis B virus carrier rate variation is 1-20% worldwide. This 
variation is related to differences in the route of transmission and the 
patient’s age at infection. In the areas of low prevalence (rate of 0.1-2%), 
the sexual and percutaneous transmission during adulthood are the main 
ways of transmission. In areas of intermediate prevalence (rate of 3-5%), 
the sexual, percutaneous and transmission during delivery are the major 
routes. In areas of high prevalence (rate of 10-20%), the predominant 
mode of transmission is perinatal, and the disease is transmitted vertically 
during early childhood from the mother to the infant31.
Although HCV infection has both acute and chronic forms, most 
of the morbidity associated with infection is realized through the 
development of chronic liver disease in a subset of infected people, years 
after initial acquisition of the infection. Thus, a major determinant of the 
future burden of disease is the past and present incidence of infection. 
However, establishing the incidence of HCV infection is difficult because 
most infections are initially asymptomatic and available assays do not 
distinguish acute from chronic or resolved infection. Acute disease 
reporting systems can underestimate the incidence of HCV infection, 
even in countries with well-established surveillance systems35.
In Brazil, the HBV vaccine was included in the National Immunization 
Program in 1996, but was implemented in the State of Santa Catarina 
in 1993 for children under five years of age and for professionals at 
risk27. The hepatitis B immunization schedule for newborns consists 
of three doses (0, 1, 6 month schedule). Besides, the program includes 
the prevention of perinatal infection, through maternal screening and 
prophylaxis of newborns, HBV vaccination for all children, to prevent 
the infection in childhood and older, vaccination of adolescents who were 
not protected and individuals belonging to risk groups. One of the goals 
of the Brazilian Health Ministry is the immunization of young people 
under 19 years of age15,27.
The HBV universal vaccination has demonstrated reduction in rates of 
infection. However, after the implementation of the vaccination routine, 
it seems useful to verify the impact of routine immunization on the 
epidemiology of the infection by analyzing the trend and the change of 
several indicators, through serum-epidemiological studies7,10. Thus, after 
over than a decade of the introduction of vaccination program against 
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HBV in Brazil27, it is necessary to verify the impact of this practice in 
the epidemiology of infection in the country.
Epidemiological surveillance for hepatitis C is also essential, even 
if there is no vaccine available. Identification of HCV-infected people 
is required to initiate prevention activities and reduce the risks for HCV 
transmission and chronic liver disease. Anti-HCV-positive individuals 
require further evaluation for chronic HCV infection and liver disease, 
and those with chronic hepatitis C require evaluation for possible antiviral 
therapy and the need for further medical management8.
In this study, the aim is to determine the prevalence of HBV and 
HCV serological markers among children and adolescents and verify the 
epidemiology of the HBV infection over than a decade of the introduction 
of vaccination program.
MATERIALS AND METHODS
Study design: We conducted a cross-sectional study to evaluate the 
prevalence of serological markers for HBV and HCV among children 
and adolescents.
Studied population: The amostral size was calculated based on the 
statistical formula n @ 4z 
a
2
 p q / (2ME)2, being z 
a
 = z value of the normal 
curve in the (usually bicaudal), p = initial estimate of the proportion, q = 
p-complement (1-p) and ME = margin of error on the maximum tolerable 
parameter28. Considering 0.5 the initial estimate of the proportion and 
the complement of p equal to 0.5, with prevalence of HBV and HCV 
markers of 50% with a 95% confidence interval and 0.05 alpha error, 
it was demonstrated to be necessary 384 participants. An amostral plan 
was designed, aiming to reproduce the distribution of the population of 
children and adolescents attended by the Programa de Saúde da Família 
in health posts in the city of Blumenau. It was evaluated about 10 to 
30 volunteers in each health unit visited, being those 17 out of 40. The 
sample was composed of 393 children and adolescents attended at these 
health institutions in the period between October 2007 and August 2008. 
The participants were included by randomized selection.
Data processing and analysis: Inclusion criteria were age between 
10 to 15 years and presentation of an informed consent signed by parents 
or responsible ones. 
Blood samples were collected by venipuncture in the health 
institutions selected for the survey, to determine the serologic markers 
HBsAg, total anti-HBc and anti-HCV. After separation of the serum, 
the samples were stored at - 20 °C to perform the serological tests. The 
analysis of blood samples was performed in the Municipal Laboratory 
of the city of Blumenau, Santa Catarina State, Brazil. 
Vaccination data of the participants who had presented hepatitis B 
virus infection markers had been verified in the vaccination document. All 
participants who were positive for HBV infection markers had presented 
three doses of vaccine in the vaccination certificate.
Serologic testing: HBsAg, total anti-HBc and anti-HCV were 
detected by Microparticle Enzyme Immunoassay (MEIA) with 
commercial kits AxSym® (Abbott Diagnostics, Chicago, Illinois, USA). 
The MEIA is a variation of the principle of Enzyme Immunoassay (EIA) 
and the solid phase comprises microparticles that increase the sensitivity 
of the method. This solid phase EIA uses the antigens and/or antibody 
adsorbed on the surface for the binding of complementary analytes. The 
bound analyte is detected by a number of antibody-antigen reactions. 
The EIA that qualitatively detects the surface antigen of hepatitis B virus 
(HBsAg) in human serum or plasma uses microparticles coated with 
anti-HB monoclonal antibodies. In the same way, those who qualitatively 
detect the total anti-HBc and anti-HCV recombinant antigens have 
adsorbed the microparticles in the solid phase.
Ethical approval: This study was approved by the Ethics Committee 
in Human Research at the Federal University of Santa Catarina, in the 
Protocol n. 238/07, and approved by the Health Secretary in Blumenau.
RESULTS
The population was composed of 393 children and adolescents. 
Among the participants, 210 were female (53.44%) and 183 were male 
(46.56%). The age range was 10 - 15 years, and the mean age was 12.5 
years (± 1.7). The most frequent age group was between 12 and 13 years 
(40.20%). Table 1 refers to the general characterization of the sample, 
with the population distribution according to sex and age. 
The seropositivity for HBsAg was found in 0.76% of the samples 
(3/393) and total anti-HBc was 1.02% (4/393). Copositivity between 
HBsAg and total anti-HBc was detected in 0.76% (3/393). The 
seropositivity for HBV, which means positive samples that reacted with 
one or two tested markers (HBsAg and total anti-HBc), was 1.02% 
(4/393) (Table 2). In the evaluation of the 393 samples for anti-HCV, no 
case of positivity for the antibody was found.
All volunteers that were positive for HBsAg marker received three 
doses of hepatitis B vaccine. 
Table 1
 Population distribution according to sex and age
Variable Population
Sex
Female 210 (53.44%)
Male 183 (46.56%)
Age (years)
10-11 105 (26.72%)
12-13 158 (40.20%)
14-15 130 (33.08%)
Table 2
 HBV markers in the studied population
Serologic marker Positive (n) %
Total anti-HBc 1 0.25%
Total anti-HBc + HBsAg 3 0.76%
No marker 389 98.98%
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DISCUSSION
Chronic HBV and HCV infections are the most important causes of 
hepatocellular carcinoma (HCC), the fifth most common solid tumor in 
the world. The incidence and prevalence of HCC is rising in the United 
States and in Europe, and costs of care in HCC will continue to rise14. 
In the United States, the total economic burden of HCC in 2005 was 
estimated to be $454.5 million22. The development of more effective and 
cost-effective treatments for viral hepatitis and related complications is 
a challenge for the medical community23. Therefore, interventions to 
reduce the prevalence of HBV and HCV infections may yield substantial 
economic benefits.
The seroprevalence of anti-HCV among children and adolescents 
found in this study is in agreement with that observed in Spain32, and 
lower than that reported in the United States20, in Germany16 and in 
Pakistan19. The results of our study show a low circulation of the hepatitis 
C virus among the studied population, possibly due to the low exposure 
to risk factors for HCV infection. The risk factors most frequently cited 
as accounting for HCV transmission worldwide are injecting drug use 
and blood transfusions4,11,12. 
There is a lack of data about HCV infection in pediatric and adolescent 
population in Brazil. Anti-HCV seroprevalence reports in Blumenau are 
available among people submitted to blood testing in a laboratory (1.6%)21 
and blood donors (0.59%)33. Studies among blood donors revealed an 
overall confirmed anti-HCV seroprevalence of 0.35% in Santa Catarina33, 
0.9% in Rio de Janeiro2 and 1.2% in Ribeirão Preto42. In a multi-center 
study of HCV seroprevalence among first time Brazilian blood donors, 
the frequency of anti-HCV was 0.97% in women and 0.38% in men29. 
In relation to adult populations, the awareness of HCV infection among 
children and adolescents is limited. Nevertheless, compared to adults, 
the prevalence of this infection was lower, and horizontal transmission 
from adult to child in a household does not appear to be an important 
risk factor in the studied population.
The prevalence for HBsAg and for total anti-HBc reported here 
was higher than that found among adolescents in Portugal3 and among 
children and adolescents under 15 years of age in Saudi Arabia26. The 
prevalence of these markers reflects a higher exposure to risk factors 
for HBV infection in the studied population. Moreover, low educational 
level, low socio-economic status and perinatal transmission may also be 
associated with the higher prevalence. However, hepatitis B infection is 
more commonly transmitted in children through the horizontal route1,13, 30.
Although the vaccination is the most effective strategy to prevent 
HBV infection, in our study half of non-infected participants showed 
antibodies to hepatitis B surface antigen below 10 mIU/mL (data not 
shown), and we found three cases of HBsAg in vaccinated individuals. 
These individuals may not have received the hepatitis B vaccine at birth 
and may have been exposed to the virus before vaccination. Furthermore, 
some other hypothesis such as mutations in the virus surface antigen18 
and intrauterine transmission of HBV from mothers to the fetus40 have 
been proposed to explain the HBV infection in vaccinated individuals. 
In this study, transmission of HBV to infants born from HBV carrier 
mothers cannot be ruled out. However, HBsAg status of mothers was 
not established. In addition, another limitation is the lack of virological 
data investigating possible vaccine escape mutants. 
In the present study, the prevalence for anti-HBc alone was 0.25%. 
Worldwide, the prevalence of isolated anti-HBc in different populations 
ranged from 0.1 to 20%9,17,36,41. In Taiwan, one study with 1200 children 
aged seven years with complete HBV immunization in infancy showed 
that eleven children had new HBV infections with anti-HBc positivity as 
the only marker, and none became positive for HBsAg or had detectable 
HBV DNA by polymerase chain reaction. The percentage of protective 
anti-HBs in children without booster vaccination decreased from 71.1% 
at age seven years to 37.4% at age 12 years, but only one of 200 children 
who received a booster dose and two of 258 children who did not received 
had developed new anti-HBc positivity24. National vaccination program 
has decreased the spread of anti-HBc alone in this country25. In a 10-year 
follow-up study conducted in a community with a high spread of HBV 
infection, 0.8% had developed anti-HBc yet none showed a clinically 
significant breakthrough infection43. Another study showed that three out 
of 19,000 individuals who had developed HCC were HBsAg negative 
but were anti-HBc positive. This might suggest that there is a very small 
risk of HCC among those who have anti-HBc as the only indication of 
a previous infection6.
The present study showed that seropositivity for HBV infection 
among children and adolescents from Blumenau was lower than that 
recorded among people submitted to blood testing in a laboratory 
(38.5%)21 and blood donors (9.25%)33 in the same city. The overall 
prevalence rate of HBV infection in the studied population was also 
smaller than that found among blood donors in Santa Catarina (5.35%)33, 
Rio de Janeiro (3.68%)2, Acre (54.8%)38 and Ribeirão Preto (8.7%)42. 
Other authors have reported higher prevalence of HBV markers in older 
ages. In a rural area in the Amazon Region of Mato Grosso State, the 
overall seroprevalence of HBV markers was 40.0%39. The prevalence of 
serological markers of HBV infection was 11.1% in healthcare workers 
in Mato Grosso do Sul State34, and 24.1% among laboratory staff in 
Goiânia37. One study carried out among dentists from Campo Grande, 
Mato Grosso do Sul, showed 10.8% of seropositivity for HBV infection5.
The higher prevalence of HBV markers in older ages could be 
due to the greater number of years of potential exposure and the lack 
of awareness of HBV infection in earlier decades13. In addition, the 
vaccination may have contributed to this lower prevalence among 
children and adolescents aged 10-15 years. The low prevalence of HBV 
infection markers indicates the positive impact of routine infant hepatitis 
B vaccination, which was included in the National Immunization Program 
in 199627, in the prevention of transmission in the studied population. 
In conclusion, the prevalence of HBV infection was higher than 
HCV infection in the studied population. Until a safe and effective 
vaccine against HCV is available, information and educational 
campaigns regarding modes of transmission are the main preventive 
tools to reduce the burden of HCV infection and HCV-related disease. 
The data from our study show that the seroprevalence of HBV infection 
markers among children and adolescents in the southern Brazilian 
region, over than a decade of the introduction of vaccination program, 
is higher when compared to the other countries. This result reinforces 
the importance of HBV vaccination initiated at birth, to prevent perinatal 
HBV transmission, and the necessity of preventive measures including 
educational activities in addition to the universal childhood HBV 
vaccination, to further reduce the morbimortality and the economic 
impact associated with the disease.
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RESUMO
Soroprevalência dos marcadores de infecção das hepatites B e C 
em crianças e adolescentes da região sul do Brasil
As infecções pelo vírus da hepatite B (HBV) e pelo vírus da hepatite 
C (HCV) representam a causa de uma substancial proporção das doenças 
hepáticas em todo o mundo. O objetivo deste estudo foi determinar a 
prevalência dos marcadores sorológicos do HBV e do HCV em crianças 
e adolescentes, e verificar a epidemiologia da infecção pelo HBV passada 
uma década desde a introdução do programa de vacinação. Os marcadores 
sorológicos HBsAg, anti-HBc total e anti-HCV foram avaliados em 393 
amostras. A soropositividade para o HBsAg foi de 0,76% e para o anti-
HBc total foi de 1,02%. Co-positividade entre HBsAg e anti-HBc total foi 
verificada em 0,76% das amostras analisadas. Não houve soropositividade 
para o marcador anti-HCV. A soroprevalência dos marcadores de infecção 
pelo HBV em crianças e adolescentes da região sul do Brasil é elevada 
em relação à reportada em outros países. Medidas preventivas, tais como 
atividades educativas além da vacinação infantil universal contra o HBV, 
devem ser iniciadas a fim de reduzir a morbimortalidade e o impacto 
econômico associados a doença. 
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